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Tumor growth and metastasis are multifaceted pro-
cesses that mainly involve cell adhesion, proteolytic
degradation of the extracellular matrix, and cell migra-
tion. Syk is a member of a tyrosine kinase family that is
expressed mostly in hematopoietic cells. Syk is ex-
pressed in cell lines of epithelial origin, but its function
in these cells remains unknown. Here we report that Syk
is expressed in MCF-7 cells but not in MDA-MB-231 cells.
The overexpression of wild type Syk kinase but not ki-
nase-negative Syk suppressed cell motility and inhib-
ited the activation of phosphatidylinositol (PI) 3-kinase
in MDA-MB-231 cells. In contrast, when Syk-specific an-
tisense S-oligonucleotide but not the sense S-oligonu-
cleotide was transfected to MCF-7 cells the level of PI
3-kinase activity as well as cell motility were increased.
The MDA-MB-231 cells transfected with wild type Syk
cDNA followed by treatment with piceatannol, a Syk
inhibitor, enhanced cell motility and PI 3-kinase activ-
ity. Pervanadate, a phosphotyrosine phosphatase inhib-
itor, induced PI 3-kinase activity and stimulated the
interaction between the inhibitor of nuclear factor B
(IB) and the p85 domain of PI 3-kinase through ty-
rosine phosphorylation of the IB, which ultimately
resulted in nuclear factor B (NFB) activation. Per-
vanadate had no effect on the activation of Syk in these
cells. However, Syk suppressed the NFB transcrip-
tional activation and interaction between IB and PI
3-kinase by inhibiting the tyrosine phosphorylation of
IB. Syk, PI 3-kinase inhibitors, and NFB inhibitory
peptide inhibited urokinase type plasminogen activator
(uPA) secretion and cell motility in these cells. To our
knowledge, this is the first report that Syk suppresses
the cell motility and inhibits the PI 3-kinase activity
and uPA secretion by blocking NFB activity through
tyrosine phosphorylation of IB. These data further
demonstrate a functional molecular link between Syk-
regulated PI 3-kinase activity and NFB-mediated uPA
secretion, and all of these ultimately control the motility
of breast cancer cells.
Cell migration and extracellular matrix invasion are two of
the major steps in embryonic development (1, 2), wound heal-
ing, and cancer cell metastasis (3, 4). However, the exact mo-
lecular mechanisms that regulate these processes are not well
understood. Syk, a nonreceptor protein-tyrosine kinase, is ex-
pressed widely in hematopoietic cells (5, 6). It has tandem
amino-terminal SH21 domains and a carboxyl-terminal kinase
domain (7, 8). The SH2 domains bind phosphorylated immuno-
receptor tyrosine-based activation motifs and play significant
roles in signaling through immunoreceptors (9). ZAP-70 is a
cytoplasmic tyrosine kinase, and both Syk and ZAP-70 share
the same tandem SH2 domains at the amino terminus and play
important roles in coupling antigen and Fc receptors to down-
stream signaling events that mediate diverse cellular re-
sponses including proliferation, differentiation, and phagocyto-
sis (9, 10). Fc receptors are members of the family of membrane
proteins, called immunoreceptors, and they are expressed in all
cells of the immune system. Both Syk and ZAP-70 are regu-
lated by 3 integrin-dependent cell adhesion via phosphoryla-
tion-independent interaction with the cytoplasmic domain of 3
integrin (11). The expression of Syk has also been reported in
cell lines of epithelial origin (12), but its function in these cells
is not well understood. Recently it has been documented that
Syk is commonly expressed in normal human breast tissue,
benign breast lesions, and low tumorigenic breast cancer cell
lines (13).
Several cytokines, growth factors, and other agents control
the regulation of cell motility. Phosphatidylinositol 3-kinase
(PI 3-kinase) also plays significant role in regulation of cell
motility (14). Two subunits are present among all of the classes
of PI 3-kinases. One is catalytic subunit p110 (, , ) or p110,
and the other is regulatory subunit p85 (, , p55, and p101)
(15). The regulatory subunit of PI 3-kinase is responsible for B
cell development and proliferation (16), and the catalytic sub-
units are critical for chemotactic activity (17).
The activation of NFB is regulated by a number of pro-
inflammatory stimuli (18, 19). The NFB family consists of
several members including p65, p50, RelB, and c-Rel molecules
(18). The activity of NFB is also tightly controlled by its
inhibitor, IB family of proteins (20). NFB forms a complex
with IB, and the complex can be removed from the nucleus
by exportin-mediated transport to the cytoplasm. Recent report
indicated that constitutively active PI 3-kinase controls the
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activation of NFB by the association of tyrosine-phosphory-
lated IB with the regulatory subunit of PI 3-kinase, p85
(21). The recent data also demonstrated that interleukin-1
stimulates PI 3-kinase dependent phosphorylation and trans-
activation of NFB without nuclear translocation of NFB,
indicating an alternative pathway other than IB-mediated
pathway (22). But the molecular mechanism by which Syk, a
tyrosine kinase, regulates the PI 3-kinase dependent activa-
tion of NFB in breast cancer cells is not well defined.
Urokinase-type plasminogen activator (uPA) is a member of
the serine protease family which induces the conversion of
plasminogen to plasmin (23). Plasmin regulates cell invasion
by degrading matrix proteins such as fibronectin, type IV col-
lagen, and laminin or indirectly by activating matrix metallo-
proteinases and uPA (24–26). Previous reports shown that uPA
plays a significant role in tumor growth and metastasis. The
signaling pathway by which Syk controls uPA secretion
through PI 3-kinase-dependent activation of NFB is not
clearly understood.
In this study, we demonstrate that overexpression of wild
type Syk in MDA-MB-231 cells suppressed cell motility and
reduced PI 3-kinase activity. Syk-specific antisense phospho-
rothioate oligonucleotide (ASSyk), when transfected to MCF-7
cells, increased cell motility and up-regulated PI 3-kinase ac-
tivity. Pervanadate (pV) stimulated PI 3-kinase activity and
induced transactivation of NFB through tyrosine phosphoryl-
ation of IB, whereas Syk down-regulated the NFB activity
by inhibiting tyrosine phosphorylation of IB in these cells.
Syk, PI 3-kinase inhibitor, and NFB inhibitors inhibited cell
motility and uPA secretion in these cells. Taken together, Syk
suppressed cell motility, uPA secretion, and PI 3-kinase-me-
diated NFB activation by inhibiting the interaction between
the p85 subunits of PI 3-kinase and tyrosine-phosphorylated
IB.
EXPERIMENTAL PROCEDURES
Materials—The rabbit polyclonal anti-Syk and anti-IB and mouse
monoclonal anti-PI 3-kinase, p85 antibodies were obtained from
Santa Cruz Biotechnology. The rabbit polyclonal anti-phospho-IB
and mouse monoclonal anti-uPA antibodies were purchased from On-
cogene. Piceatannol, LY294002, and ST 638 (-cyano-(3-ethoxy-4-hy-
droxy-5-phenylthiomethyl)cinnamide) were purchased from Calbio-
chem. Wortmannin and TRITC-conjugated goat anti-mouse IgG were
obtained from Sigma. The PIwas from ICN. [-32P]ATP was purchased
from the Board of Radiation and Isotope Technology (Hyderabad, In-
dia). The dual luciferase reporter assay system was obtained from
Promega. The rabbit anti-phosphotyrosine antibody and Lipo-
fectAMINE Plus reagent were purchased from Invitrogen. The FITC-
conjugated goat anti-rabbit IgG was from Pharmingen. Boyden type cell
migration chambers were obtained from Corning. All other chemicals
were analytical grade.
The pV was prepared by incubating 1 M sodium orthovanadate with
33% H2O2 in phosphate-buffered saline (pH 7.4) at room temperature
for 15 min. The pH of the solution was neutralized with 1 N HCl, and
excess H2O2 was deactivated with catalase.
Cell Culture—The MDA-MB-231 and MCF-7 cells were purchased
from ATCC (Manassas, VA). Both MDA-MB-231 and MCF-7 cells were
cultured in Dulbecco’s modified Eagle’s medium. The medium was
supplemented with 10% fetal calf serum, 100 units/ml penicillin, 100
g/ml streptomycin, and 2 mM glutamine in a humidified atmosphere of
5% CO2 and 95% air at 37 °C.
Western Blot Analysis—To detect the level of Syk expression in
MCF-7 and MDA-MB-231 cells, the cells were lysed in lysis buffer (1%
Triton X-100 solution containing 1 mM phenylmethylsulfonyl fluoride,
20 g/ml leupeptin, and 2 mM EDTA). The cleared lysates were collected
by centrifugation at 12,000  g for 15 min at 4 °C. The protein concen-
tration in the lysates was measured by Bio-Rad protein assay. The
lysates containing equal amounts of total proteins were resolved by
SDS-PAGE. The proteins were electrotransferred from gel to nitrocel-
lulose membrane. The membranes were incubated with rabbit poly-
clonal anti-Syk antibody (1:200) and incubated further with anti-rabbit
horseradish peroxidase-conjugated IgG (1:1,000). The membrane was
washed and detected by the enhanced chemiluminescence (ECL) detec-
tion system (Amersham Biosciences) according to the manufacturer’s
instructions. To check the tyrosine phosphorylation of Syk, both MCF-7
and MDA-MB-231 cell lysates were immunoprecipitated individually
with anti-Syk antibody. The immunoprecipitated samples were re-
solved by SDS-PAGE and detected by Western blot analysis using
rabbit anti-phosphotyrosine antibody as described above. These blots
were reprobed with anti-actin antibody as loading control.
DNA Transfection—The wild type and kinase-negative Syk (SykK)
cDNAs in an expression vector (pcDNA 3.1) were a generous gift from
Dr. Susette C. Mueller (Department of Oncology, Georgetown Univer-
sity Medical School, Washington, D. C.). The MDA-MB-231 cells were
split 12 h prior to transfection in Dulbecco’s modified Eagle’s medium
containing 10% fetal calf serum. The cells were transiently transfected
with Syk cDNA using LipofectAMINE Plus according to the manufac-
turer’s instructions. Briefly, wild type or SykK cDNA (8 g) was mixed
with Plus reagent, and then cDNA reagent Plus was incubated with
LipofectAMINE. The LipofectAMINE Plus cDNA complex was added to
the cells and incubated further at 37 °C for 12 h. The control cells
received LipofectAMINE Plus alone. The cell viability was detected by
a trypan blue dye exclusion test. After incubation, the medium was
removed, and the cells were refed with fresh medium and maintained
for an additional 12 h. These transfected cells were used for the detec-
tion of Syk and uPA expression by Western blot analysis, NFB activity
by luciferase assay, and PI 3-kinase activity by kinase assay. These
cells were also used for a migration assay. In separate experiments,
MCF-7 cells were transfected with Syk-specific S-oligonucleotides ac-
cording to the methods described above. Human ASSyk (5-TGC CGC
TGC TGG CCA TGC TT-3) and SSyk (5-AAG CAT GGC CAG CAG
CGG CA-3) with phosphorothioate linkages were synthesized (Geno-
mechanix). These oligonucleotides were purified by column chromatog-
raphy, and purity was checked by PAGE. These oligonucleotide-trans-
fected cells were used for the detection of Syk and uPA expression by
Western blot analysis, NFB luciferase assay, and PI 3-kinase assay.
These transfected cells were also used for a cell migration assay. To
check the dose-dependent response, separate transfection experiments
were performed with different doses (0–10 g) of ASSyk.
Cell Migration Assay—The migration assay was conducted using a
Transwell cell culture chamber according to the standard procedure as
described previously (27). Briefly, the Syk-specific S-oligonucleotide-
transfected MCF-7 cells or Syk cDNA-transfected MDA-MB-231 cells
were harvested with trypsin-EDTA and centrifuged at 800  g for 10
min. The cell suspension (5  105 cells/well) was added to the upper
chamber of the prehydrated polycarbonate membrane filter. The lower
chamber was filled with fibroblast-conditioned medium, which acted as
chemoattractant. In a separate experiment, either wild type Syk
cDNA-transfected MDA-MB-231 or nontransfected MCF-7 cells were
incubated in the absence or presence of 0–20 M piceatannol, a Syk
inhibitor, at 37 °C for 30 min and used for a migration assay. In other
experiments, both of these nontransfected cells were treated individu-
ally with a PI 3-kinase inhibitor (0–100 nM wortmannin or 0–10 M
LY294002) at 37 °C for 3 h or with 250 M pV, a tyrosine phosphatase
inhibitor, at 37 °C for 30 min or in combination and used for migration
assay. To check whether NFB or uPA is involved in migration, both of
these nontransfected cell lines were treated individually with 100 g/ml
SN-50, 100 g/ml SN-50M, 10 g/ml actinomycin-D, 50 M curcumin, 5
ng/ml PMA, 10 g/ml monoclonal uPA antibody at 37 °C for 6 h. The
transfected cells were also treated with anti-uPA antibody and used for
migration assay. After treatment, these cells were incubated in a hu-
midified incubator in 5% CO2 and 95% air at 37 °C for 16 h. The
nonmigrated cells on the upper side of the filter were scraped, and the
filter was washed. The migrated cells in the reverse side of the filter
were fixed with methanol and stained with Giemsa. The migrated cells
on the filter were counted under an inverted microscope (Olympus). The
experiments were repeated in triplicate. Preimmune IgG served as
nonspecific control. These treated cells were also used for the detection
of uPA by Western blot analysis.
Immunoprecipitation and in Vitro Kinase Assay—To examine the
autophosphorylation of Syk in MCF-7 and MDA-MB-231 cells, the cells
were immunoprecipitated with rabbit polyclonal anti-Syk antibody and
subjected to the the kinase assay. Briefly, the cells were lysed in lysis
buffer (1% Triton X-100 solution containing 1 mM phenylmethylsulfonyl
fluoride, 20 g/ml leupeptin, and 2 mM EDTA), and the protein concen-
tration in the cleared lysates was measured by Bio-Rad protein assay.
The samples containing equal amounts of total proteins were immuno-
precipitated with rabbit polyclonal anti-Syk antibody according to the
manufacturer’s instructions (Roche Molecular Biochemicals). The im-
munoprecipitated samples were incubated with 2 Ci of [-32P]ATP in
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kinase assay buffer (50 mM Hepes buffer (pH 8.0) containing 10 mM
Na3VO4, 50 mM MgCl2, and 5 mM MnCl2) at 30 °C for 10 min. The
samples were resolved by SDS-PAGE, dried, and autoradiographed. In
separate experiments, the MCF-7 cells were treated in the absence or
presence of 250 M pV for 0–60 min. The cell lysates were immunopre-
cipitated with anti-Syk antibody, and a Syk kinase assay was per-
formed as described above.
To check the role of Syk in the regulation of PI 3-kinase activity, the
MCF-7 cells were transfected with SSyk or ASSyk, the MDA-MB-231
cells were transfected with wild type or SykK cDNA, and the PI
3-kinase activity was measured. Cells were lysed in lysis buffer as
described earlier and centrifuged at 12,000  g for 15 min. The cleared
lysates were collected, and the protein concentration was measured by
Bio-Rad protein assay. The PI 3-kinase assay was performed with
slight modification (28). Briefly, cell lysates were immunoprecipitated
with mouse monoclonal anti-p85 antibody, and the immunoprecipi-
tated samples were incubated in kinase assay buffer (25 mM Hepes (pH
7.4), 10 mM MgCl2, and 1 mM EDTA) containing 0.25 mg/ml phosphati-
dylinositol, 100 mM ATP, and 15 Ci of [-32P]ATP and incubated at
30 °C for 10 min. The reaction was terminated by the addition of
acidified chloroform:methanol (2:1). Lipids were extracted according to
the procedure described previously (29) and separated on oxalate-
treated plastic TLC plates using a solvent system consisting of chloro-
form, methanol, and 20% methylamine (65:35:10 v/v/v). The spots cor-
responding to the position of radioactive phosphatidylinositol
phosphate (PIP) were visualized by autoradiography. In separate ex-
periments, wild type Syk cDNA-transfected MDA-MB-231 or nontrans-
fected MCF-7 cells were individually treated with 0–10 M piceatannol,
a Syk kinase inhibitor, at 37 °C for 30 min and used for the PI 3-kinase
assay. In other experiments, nontransfected MDA-MB-231 or MCF-7
cells were also pretreated with 250 M pV at room temperature for 0–30
min and used for the PI 3-kinase assay.
To check the role of pV on the tyrosine phosphorylation of IB and
subsequent interaction between IB and PI 3-kinase, both MCF-7
and MDA-MB-231 cells were treated individually with 250 M pV
tyrosine phosphatase inhibitor for 0–30 min, and the total proteins in
the lysates were measured by Bio-Rad protein assay. Half of the lysates
were immunoprecipitated with nonphosphorylated anti-IB antibody.
The immunoprecipitated samples were resolved by SDS-PAGE, and the
level of tyrosine-phosphorylated IB was detected by Western blot
analysis using anti-phosphotyrosine antibody. The remaining half of
the lysates was resolved by SDS-PAGE, and the serine-phosphorylated
IB was detected by Western blot analysis using anti-phospho-IB
(serine-specific) antibody. Similarly, both MCF-7 and MDA-MB-231
cells were treated individually in the absence or presence of 250 M pV
alone or with 100 M ST 638, a tyrosine kinase inhibitor, along with 250
M pV at 37 °C for 0–30 min. The cells were lysed, and the lysates were
immunoprecipitated with anti-PI 3-kinase, p85 antibody. The immu-
noprecipitated samples were resolved by SDS-PAGE, and the tyrosine
phosphorylation of IB in lysates was detected by Western blot anal-
ysis using rabbit anti-phosphotyrosine antibody. The blots were rep-
robed with anti-actin antibody as loading control.
To check the effect of Syk on tyrosine phosphorylation of IB and
subsequent interaction between IB and PI 3-kinase, the Syk-specific
S-oligonucleotide-transfected MCF-7 or Syk cDNA-transfected MDA-
MB-231 cells were treated individually with 250 M pV for 15 min, and
the cells were lysed in lysis buffer. Total proteins in the lysates were
measured by Bio-Rad protein assay. The cell lysates containing equal
amounts of total proteins were immunoprecipitated with anti-p85
antibody. The samples were resolved by SDS-PAGE and analyzed by
Western blot analysis using anti-phosphotyrosine antibody. The blots
were reprobed with anti-actin antibody.
Immunofluorescence Study—Both MDA-MB-231 and MCF-7 cells
were grown in monolayer on glass slides and then treated individually
in the absence or presence of 250 M pV at room temperature for a
period of 0–30 min. The cells were fixed with paraformaldehyde for 10
min, blocked with 5% bovine serum albumin for 30 min, and washed
with phosphate-buffered saline (pH 7.4). The fixed cells were incubated
with a mixture of mouse monoclonal anti-PI 3-kinase, p85 (1:10
dilution), and rabbit polyclonal anti-IB antibodies (1:20 dilution) at
room temperature for 2 h. The cells were washed with phosphate-
buffered saline (pH 7.4) and incubated with a mixture of FITC-conju-
gated anti-rabbit IgG and TRITC-conjugated anti-mouse IgG. The cells
were washed, mounted with coverslips, and analyzed under confocal
microscopy (Zeiss).
NFB Luciferase Reporter Gene Assay—The semiconfluent MCF-7
cells grown in 24-well plates were transiently transfected with Syk-
specific S-oligonucleotides and a luciferase reporter construct (pNFB-
Luc) containing five tandem repeats of the NFkB binding site (a gen-
erous gift from Dr. Rainer de Martin, University of Vienna, Vienna,
Austria) using LipofectAMINE Plus reagent for 12 h. Similarly, the
MDA-MB-231 cells were transfected with wild type or SykK cDNA and
pNFB-Luc under the same conditions described above. The transfec-
tion efficiency was normalized by cotransfecting the cells with pRL
vector (Promega) containing a full-length Renilla luciferase gene under
the control of a constitutive promoter. In separate experiments, MCF-7
cells transfected with pNFB-Luc or MDA-MB-231 cells transfected
with wild type Syk and pNFB-Luc were treated with 0–10 M piceat-
annol. In other experiments, both MCF-7 and MDA-MB-231 cells were
transfected individually with pNFB-Luc and treated with either 100
M pV alone for 30 min, pV with 1–100 nM wortmannin or 1–10 M
LY294002 for 3 h. Cells were harvested in passive lysis buffer (Pro-
mega). The luciferase activities were measured by luminometer (Lab
Systems) using the dual luciferase assay system according to the man-
ufacturer’s instructions (Promega). Changes in luciferase activity with
respect to the control were calculated.
RESULTS
Detection of Tyrosine-phosphorylated Syk Expression by
Western Blot Analysis and Autophosphorylation by in Vitro
Kinase Assay—The expression of Syk was analyzed by SDS-
PAGE followed by Western blot in MCF-7 (Fig. 1A, lane 1) and
MDA-MB-231 (lane 2) cells. To assess the autophosphorylation
activity of Syk, both of these cell lines were lysed in lysis buffer,
and the lysates were immunoprecipitated with rabbit poly-
clonal anti-Syk antibody. The immunoprecipitated samples
were incubated with [-32P]ATP in kinase assay buffer. The
samples were resolved by SDS-PAGE and autoradiographed.
Fig. 1B shows the autophosphorylated Syk expression in
MCF-7 cells (lane 1), but this was absent in MDA-MB-231 cells
(lane 2). To check whether the phosphorylation of Syk is ty-
rosine-specific, both of the cell lysates were immunoprecipi-
tated with anti-Syk antibody and detected by Western blot
analysis using rabbit anti-phosphotyrosine antibody. The
MCF-7 (Fig. 1C, lane 1) but not MDA-MB-231 (lane 2) cells
recognized tyrosine-phosphorylated Syk expression, suggesting
that tyrosine residue of Syk is involved in autophosphorylation.
All of these blots were reprobed with anti-actin antibody as
loading control. To check whether pV, a tyrosine phosphatase
inhibitor, has any role in the autophosphorylation activity of
Syk, the MCF-7 cells were treated with 250 M pV for 0–60
min, and the cell lysates were immunoprecipitated with anti-
Syk antibody. The activity of Syk in the immunoprecipitated
samples was detected by kinase assay, and the results showed
that pV had no effect on Syk activity in these cells (Fig. 1D,
lanes 1–5).
To control the expression of Syk and to check the status of
Syk-dependent downstream signaling events and cell motility,
the low invasive MCF-7 cells were transfected with Syk-specific
phosphorothioate-linked SSyk or ASSyk oligonucleotides in the
presence of LipofectAMINE Plus. The expression of Syk was
detected by Western blot analysis, and the data indicated that
there was significant expression of Syk in cells transfected with
LipofectAMINE Plus alone (Fig. 2A, lane 1) or SSyk transfected
cells (lane 2), but the level of Syk was reduced drastically when
cells were transfected with ASSyk (lane 3). Similarly, the
MDA-MB-231 cells were transfected with wild type or SykK
cDNA in the presence of LipofectAMINE Plus, and expression
of Syk was determined by Western blot analysis. The expres-
sion of Syk was absent in cells transfected with LipofectAMINE
Plus alone (Fig. 2B, lane 1), whereas a significant level of Syk
expression was observed in both wild type (lane 2) and SykK
-transfected cells (lane 3) . The level of Syk was also quantified
densitometrically and analyzed statistically (Fig. 2, A and B,
lower panels). These transfected cells were used for cell migra-
tion assays and for the detection of downstream signaling
molecules.
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Syk and PI 3-kinase Play Critical Roles in Cell Migra-
tion—To ascertain the roles of Syk and PI 3-kinase in the
regulation of cell migration, both MDA-MB-231 and MCF-7
cells were used for the migration assay. The MCF-7 cells were
transfected with Syk-specific S-oligonucleotides and performed
the migration assay. The data demonstrated that ASSyk-trans-
fected cells showed a dramatic increase of cell migration (252%)
compared with the cells transfected with LipofectAMINE Plus
alone (100%) or SSyk-transfected cells (98%) (Fig. 3A). Simi-
larly, in the highly invasive MDA-MB-231 cells, when trans-
fected with wild type Syk cDNA, there was drastic reduction of
cell migration (24%) compared with cells transfected with Li-
pofectAMINE Plus alone (100%) or SykK-transfected cells
(97%) (Fig. 3B). These data suggest that wild type Syk sup-
pressed cell migration, whereas SykK had no effect on sup-
pression of cell migration. Pretreatment of MCF-7 cells with
increasing concentrations of piceatannol (0–20 M), a Syk in-
hibitor followed by migration assays, enhanced cell migration
(100–258%) in a dose-dependent manner (Fig. 3C). To prove
further the role of piceatannol on migration of wild type Syk-
transfected MDA-MB-231 cells, the transfected cells were
treated with different doses of piceatannol (0–10 M), and then
the migration assay was conducted. The results indicated that
there was enhancement of cell migration (37–98%) when the
cells were transfected with wild type Syk followed by treatment
with increasing concentrations of piceatannol compared with
piceatannol-untreated, wild type Syk-transfected (25%) cells
(Fig. 3D). The SykK-transfected cells showed 98% migration,
whereas the number of cells that migrated using Lipo-
fectAMINE Plus-transfected cells were considered as 100%
(Fig. 3D). The SykK-transfected cells had no effect on sup-
pression of cell migration in MDA-MB-231 cells. We also stud-
FIG. 1. Expression and autophosphorylation of Syk in breast cancer cells. A, equal amounts of total proteins in cell lysates from MCF-7
and MDA-MB-231 cells were resolved by SDS-PAGE and analyzed by Western blot using rabbit polyclonal anti-Syk antibody. Lane 1, MCF-7 cells;
lane 2, MDA-MB-231 cells. B, equal amounts of total proteins in both cell lysates were immunoprecipitated with rabbit polyclonal anti-Syk
antibody, and the immunoprecipitates were incubated with 2 Ci of [-32p]ATP in kinase assay buffer as described under “Experimental
Procedures.” The sample was resolved by SDS-PAGE and autoradiographed. Lane 1, MCF-7 cells; lane 2, MDA-MB-231 cells. C, cell lysates
containing equal amounts of total proteins were immunoprecipitated with anti-Syk antibody, and the immunocomplex was resolved by SDS-PAGE
and analyzed by Western blot using rabbit anti-phosphotyrosine antibody. Lane 1, MCF-7 cells; lane 2, MDA-MB-231 cells. The arrow indicates
the Syk-specific band. As loading controls, all of these blots were reprobed with goat polyclonal anti-actin antibody (lower panels in A–C). D, effect
of pV on autophosphorylation activity of Syk in MCF-7 cells. The cells were treated with 250 M pV for 0–60 min, and the cell lysates containing
equal amounts of total proteins were immunoprecipitated with anti-Syk antibody. The immunoprecipitates were incubated with 2 Ci of
[-32p]ATP in kinase assay buffer as described above. The sample was resolved by SDS-PAGE and autoradiographed. Lane 1, control; lane 2, pV
5 min; lane 3, pV 15 min; lane 4, pV 30 min; and lane 5, pV 60 min.
FIG. 2. Detection of Syk in Syk-specific S-oligonucleotide-transfected MCF-7 and Syk cDNA transfected-MDA-MB-231 cells by
Western blot analysis. A, MCF-7 cells were transiently transfected with SSyk or ASSyk with LipofectAMINE Plus. The cell lysates containing
equal amounts of total proteins were resolved by SDS-PAGE and analyzed by Western blot using anti-Syk antibody. Lane 1, with LipofectAMINE
Plus; lane 2, with SSyk; lane 3, with ASSyk. B, MDA-MB-231 cells were transiently transfected with wild type or SykK cDNA in pcDNA 3.1 with
LipofectAMINE Plus. Equal amounts of total proteins in cell lysates were separated by SDS-PAGE and analyzed by Western blot using anti-Syk
antibody. Lane 1, with LipofectAMINE Plus; lane 2, with wild type Syk cDNA; lane 3, with SykK cDNA. The arrow indicates the Syk-specific
band. The expression of Syk was quantified by densitometric analysis and is represented in the form of a bar graph. The mean value of triplicate
experiments is indicated in the lower panels of A and B.
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ied the effects of wortmannin and LY294002 (PI 3-kinase
inhibitors) on the migration of MCF-7 and MDA-MB-231 cells.
Both MCF-7 and MDA-MB-231 cell lines were treated individ-
ually with different doses of wortmannin (0–100 nM) or
LY294002 (0–10 M) as described earlier and used for cell
migration assays. The results indicated that both of these in-
hibitors independently suppressed the cell migration of MCF-7
(Fig. 3E) and MDA-MB-231 (Fig. 3F) cells in a dose-dependent
manner. These data further suggested that PI 3-kinase plays
significant roles in regulating cell migration in these cells. To
investigate whether pV, a tyrosine phosphatase inhibitor, reg-
ulates PI 3-kinase dependent cell migration, both cell lines
were treated with 250 M pV in the absence or presence of
0–100 nM wortmannin or 0–10 M LY294002 and used for the
migration assay. The data demonstrated that pV induced mi-
gration in both cell lines. However, pV-induced migration is
suppressed by wortmannin or LY294002 (PI 3-kinase inhibi-
tors) in these cells (Fig. 3, E and F).
Syk Down-regulates PI 3-Kinase Activity in MCF-7 (Low
Invasive) and MDA-MB-231 (Highly Invasive) Cells—To check
the role of Syk in suppression of PI 3-kinase activity in MCF-7
and MDA-MB-231 cells, a PI 3-kinase assay was performed
under different conditions. These cells were lysed individually
in lysis buffer, and the lysates containing equal amounts of
total proteins were immunoprecipitated with anti-p85 anti-
body. The immunoprecipitated samples were used for the ki-
nase assay. The radioactive PIP was separated by TLC and
visualized by autoradiography. The activity of PI 3-kinase was
higher in MDA-MB-231 cells (Fig. 4A, lane 2) compared with
MCF-7 cells (lane 1). The MCF-7 cells were transfected with
Syk-specific S-oligonucleotides, immunoprecipitated with anti-
p85 antibody, and used for the PI 3-kinase assay. The MCF-7
cells transfected with ASSyk showed a higher level of PI 3-
kinase activity (Fig. 4B, lane 3) compared with LipofectAMINE
Plus alone (lane 1) or SSyk-transfected (lane 2) cells. These
data suggested that Syk suppressed PI 3-kinase activity in
MCF-7 cells. Moreover, our previous data indicated that
MCF-7 cells transfected with ASSyk showed enhancement of
FIG. 3. A, effect of transfection of MCF-7 cells with Syk-specific S-oligonucleotides on cell migration. The cells were transiently transfected with
SSyk or ASSyk using LipofectAMINE Plus. The transfected cells (5  105 cells/well) were used for cell migration assay as described under
“Experimental Procedures.” The cells transfected with ASSyk showed a dramatic increase of cell migration compared with cells transfected with
SSyk or LipofectAMINE Plus alone. B, effect of transfection of MDA-MB-231 cells with wild type or SykK cDNA on cell migration. The cells were
transfected with wild type or SykK cDNA, and the transfected cells were used for the cell migration assay. The cells transfected with wild type
Syk cDNA showed a drastic reduction of cell migration compared with cells transfected with SykK or with LipofectAMINE Plus alone. C, effect
of piceatannol, a Syk inhibitor, on migration of MCF-7 cells. The cells were pretreated with 0–20 M piceatannol at 37 °C for 30 min and then used
for migration assay. Piceatannol enhanced the migration in a dose-dependent manner. D, effect of piceatannol on migration of Syk cDNA
transfected MDA-MB-231 cells. The cells transfected with wild type Syk cDNA were treated with increasing concentrations (0–10 M) of
piceatannol and used for the migration assay as described above. Wild type Syk cDNA-transfected cells treated with increasing concentrations of
piceatannol showed enhancement of cell migration compared with nontreated, wild type Syk cDNA-transfected cells. Cells transfected with SykK
or with LipofectAMINE Plus alone showed maximum migration. E, effect of pV and a PI 3-kinase inhibitor (wortmannin or LY294002) on
migration of MCF-7 cells. MCF-7 cells were treated individually with pV, wortmannin, LY294002, or with a combination of pV and wortmannin
or pV and LY294002 and used for migration assay as described under “Experimental Procedures.” Wortmannin and LY294002 independently
reduced the migration in a dose-dependent manner, whereas pV induced the migration. pV-induced migration was also blocked by wortmannin or
LY294002. F, effect of pV and PI 3-kinase inhibitor (wortmannin or LY294002) on migration of MDA-MB-231 cells. MDA-MB-231 cells were
treated individually with pV, wortmannin, and LY294002 under different conditions as described above and used for migration assay. Wortmannin
and LY294002 reduced migration, whereas pV induced it. The pV-induced migration was also inhibited by wortmannin or LY294002. In all of these
experiments, the results are expressed as the means  S.E. of three determinations.
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cell migration compared with SSyk-transfected cells. These
data further demonstrated that Syk suppressed the cell migra-
tion by inhibiting the PI 3-kinase activity in MCF-7 cells (Figs.
3A and 4B).
The MDA-MB-231 cells were transfected with SykK or wild
type Syk cDNA, cell lysates were immunoprecipitated with
anti-p85 antibody, and the kinase assay was performed. The
cells transfected with wild type Syk cDNA reduced the PI
3-kinase activity (Fig. 4C, lane 3) compared with Lipo-
fectAMINE Plus-transfected cells (lane 1) or cells transfected
with SykK (lane 2). Because Syk suppressed the PI 3-kinase
activity, we sought to determine whether piceatannol, a Syk
inhibitor, reversed the PI 3-kinase activity. Accordingly, MDA-
MB-231 cells were transfected with wild type Syk cDNA,
treated with different doses of piceatannol (0–10 M), and then
the kinase assay was conducted. The results demonstrated that
piceatannol dose-dependently increased the PI 3-kinase activ-
ity in these cells (Fig. 4D, lanes 3 and 4) compared with un-
treated, wild type Syk-transfected cells (lane 2). The cells
transfected with LipofectAMINE Plus alone showed a higher
level of PI 3-kinase activity (lane 1). To check whether pV, a
tyrosine phosphatase inhibitor, regulates PI 3-kinase activity,
the MDA-MB-231 cells were treated with 250 M pV for 0–30
min, and then PI 3-kinase activity was measured. The results
indicated that pV induces the PI 3-kinase activity in a time-
dependent manner in these cells (Fig. 4E, lanes 1–4). Similarly,
MCF-7 cells were also treated with either piceatannol or pV
and then used for the kinase assay. The data showed that both
piceatannol (Fig. 4F, lanes 2 and 3) and pV (lanes 4 and 5)
individually enhanced PI 3-kinase activity compared with un-
treated (lane 1) MCF-7 cells. These data strongly suggested
that Syk down-regulates the PI 3-kinase activity in both
MCF-7 and MDA-MB-231 cells. All of these PIP-specific bands
were quantified by densitometric analysis and are represented
in the form of a bar graph. The mean value of triplicate exper-
iments is indicated.
Syk Suppresses pV-induced Tyrosine Phosphorylation of
IB and Subsequent Interaction between Tyrosine-phosphory-
lated IB and PI 3-Kinase—To assess the role of pV on
tyrosine phosphorylation of IB in breast cancer cells, both
FIG. 4. PI 3-kinase activity. A, equal amounts of total proteins from the lysates of MCF-7 and MDA-MB-231 cells were immunoprecipitated
with mouse monoclonal anti-p85 antibody, and the immunocomplexes were assayed for their ability to phosphorylate PI to PIP using [-32p]ATP
at 30 °C for 10 min. The PIP was resolved by TLC and autoradiographed. Lane 1, MCF-7 cells; lane 2, MDA-MB-231 cells. B, the serum-starved
MCF-7 cells were transfected with Syk-specific S-oligonucleotides, and then PI 3-kinase activity was measured as described under “Experimental
Procedures.” Lane 1, with LipofectAMINE Plus; lane 2, with SSyk; lane 3, with ASSyk. C, MDA-MB-231 cells were transfected with Syk cDNA and
used for PI 3-kinase assay. Lane 1, with LipofectAMINE Plus; lane 2, with SykK; and lane 3, with wild type Syk. D, MDA-MB-231 cells were
transfected with wild type Syk cDNA followed by treatment with increasing concentrations (0–10 M) of piceatannol at 37 °C for 30 min and used
for PI 3-kinase assay. Lane 1, with LipofectAMINE Plus alone; lanes 2–4, cells were transfected with wild type Syk cDNA and then treated with
increasing concentrations of piceatannol. Lane 2, without piceatannol; lane 3, with 5 M piceatannol; lane 4, with 10 M piceatannol. E,
MDA-MB-231 cells were treated with 250 M pV at room temperature for 0–30 min, and the cell lysates were used for the PI 3-kinase assay. Lane
1, untreated cells; lane 2, with pV for 5 min; lane 3, with pV for 15 min; lane 4, with pV for 30 min. F, MCF-7 cells were treated with 0–10 M
piceatannol for 30 min or with 250 M pV for 0–30 min and used for the PI 3-kinase assay. Lane 1, untreated cells; lane 2, with 5 M piceatannol;
lane 3, with 10 M piceatannol; lane 4, with pV for 15 min; lane 5, with pV for 30 min. In all the cases, the upper arrows indicate the PIP-specific
bands. All of these bands in A–F were quantified by densitometric analysis and are represented in the form of a bar graph. The mean value of
triplicate experiments is indicated.
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MCF-7 and MDA-MB-231 cells were treated individually with
250 M pV for 0–30 min and immunoprecipitated with anti-
IB antibody. Half of the immunoprecipitated samples were
separated by SDS-PAGE and immunoblotted with anti-phos-
photyrosine antibody. The remaining half of the samples was
analyzed by Western blot analysis using anti-IB (phospho-
serine-specific) antibody. The data demonstrated that pV in-
duces the tyrosine phosphorylation of IB in both MCF-7 (Fig.
5A, upper panel, lanes 1–4) and MDA-MB-231 (lanes 5–8) cells,
but the pV-induced tyrosine phosphorylation was higher in
MDA-MB-231 cells. In contrast, the serine phosphorylation of
IB was unchanged in both cell lines (Fig. 5A, lower panel,
lanes 1–8), suggesting that pV regulates the tyrosine phospho-
rylation but not serine phosphorylation of IB in these cells.
FIG. 5. A, role of pV in stimulation of interaction between IB and PI 3-kinase through tyrosine phosphorylation of IB. Both MCF-7 and
MDA-MB-231 cells were individually treated with pV for 0–30 min, and the cell lysates containing equal amounts of total proteins were
immunoprecipitated with nonphosphorylated anti-IB antibody. Half of the immunoprecipitated samples were resolved by SDS-PAGE and
analyzed by Western blot using anti-phosphotyrosine antibody (upper panel in A), and the remaining half of the samples were immunoblotted with
phosphoserine-specific anti-IB antibody (lower panel in A). Lanes 1–4, MCF-7 cells. Lane 1, control; lane 2, with pV for 5 min; lane 3, with pV
for 15 min; lane 4, with pV for 30 min. Lanes 5–8, MDA-MB-231 cells. Lane 5, control; lane 6, with pV for 5 min; lane 7, with pV for 15 min; lane
8, with pV for 30 min. The arrow in the upper panel of A indicates a tyrosine-phosphorylated IB-specific band, and in the lower panel of A the
arrow shows a serine-phosphorylated IB-specific band. Note that the level of tyrosine phosphorylation of IB is increased in presence of pV
(upper panel of A), but pV has no effect on serine phosphorylation of IB (lower panel of A) in both cell lines, indicating that pV induces tyrosine
phosphorylation of IB. More tyrosine phosphorylation is observed in MDA-MB-231 cells. All of these bands were quantified by densitometric
analysis, and the values of -fold changes are indicated. MCF-7 cells (B) and MDA-MB-231 cells (C) cells were treated individually with 250 M pV
at room temperature for a period of 0–30 min. In a separate experiment, the cells were also pretreated with ST 638, a protein-tyrosine kinase
inhibitor (400 nM) and then treated with 250 M pV. The cell lysates were immunoprecipitated with monoclonal anti-p85 antibody. The
immunocomplexes were resolved by SDS-PAGE and analyzed by Western blot using anti-phosphotyrosine antibody. Lane 1, control; lane 2, with
pV for 15 min; lane 3, with pV for 30 min; lane 4, with ST 638 and then with pV for 30 min. The arrows indicate the tyrosine-phosphorylated
IB-specific band. As loading controls, both of these blots were reprobed with anti-actin antibody (lower panels in B and C). D, effect of Syk-specific
S-oligonucleotides on suppression of pV-induced tyrosine phosphorylation of IB and subsequent interaction between tyrosine-phosphorylated
IB and PI 3-kinase. MCF-7 cells were transfected with Syk-specific S-oligonucleotides, and MDA-MB-231 cells were transfected with Syk cDNA
in presence of LipofectAMINE Plus. Both of these transfected cell lines were treated individually with 250 M pV and lysed in lysis buffer. The
lysates were immunoprecipitated with anti-p85 antibody. The immunoprecipitated samples were separated by SDS-PAGE and analyzed by
Western blot using anti-phosphotyrosine antibody. Lane 1, with LipofectAMINE Plus alone; lane 2, with SSyk; lane 3, with ASSyk (upper panel
of D, lanes 1–3, MCF-7 cells); lane 4, with LipofectAMINE Plus alone; lane 5, with SykK; lane 6, with wild type Syk (upper panel of D, lanes 4–6,
MDA-MB-231 cells). Note that MCF-7 cells transfected with ASSyk induced, but MDA-MB-231 cells transfected with wild type Syk reduced, the
tyrosine phosphorylation of IB. As loading controls, the same blots were reprobed with anti-actin antibody (lower panel of D). E and F, role of
pV in regulation of colocalization of IB and PI 3-kinase. MCF-7 (E) and MDA-MB-231 (F) cells were treated with 250 M pV at room temperature
for 0–30 min, fixed, and incubated with a mixture of monoclonal anti-PI 3-kinase, p85, and rabbit polyclonal anti-IB antibodies. These cells
were incubated further with a mixture of FITC-conjugated anti-rabbit IgG and TRITC-conjugated anti-mouse IgG antibodies and analyzed under
confocal microscopy. a–c, untreated cells; d–f, pV for 15 min and g–i, pV for 30 min. a, d, and g are stained with anti-PI 3-kinase, p85, and
TRITC-conjugated antibodies, respectively; b, e, and h are stained with anti-IB and FITC-conjugated antibodies, respectively; and c, f, and i are
overlapping forms of TRITC and FITC stained cells. Note that there was more colocalization of IB and PI 3-kinase, p85 in pV-treated cells (d–i)
compared with untreated cells (a–c), but higher levels of colocalization were seen in MDA-MB-231 cells.
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The bands were analyzed by densitometry, and the values of
-fold changes are indicated (Fig. 5A).
To confirm further the effects of pV on tyrosine phosphoryl-
ation of IB and regulation of interaction between phospho-
rylated IB and the p85 subunit of PI 3-kinase, both cell
lines were treated individually with pV under the same condi-
tions described above. The cell lysates were immunoprecipi-
tated with anti-p85 antibody and immunoblotted with anti-
phosphotyrosine antibody. In separate experiments, cells were
pretreated with ST 638, a protein-tyrosine kinase inhibitor,
then treated with pV, immunoprecipitated with anti-p85 an-
tibody, and detected by immunoblotting using anti-phosphoty-
rosine antibody. The data indicate that pV induces the inter-
action between IB and p85 subunit of PI 3-kinase through
tyrosine phosphorylation of IB in MCF-7 (Fig. 5B, upper
panel, lanes 1–3) and MDA-MB-231 (Fig. 5C, upper panel, lanes
1–3) cells, whereas ST 638 suppresses pV-induced tyrosine
phosphorylation in both cell lines (Fig. 5, B and C, upper panel,
lane 4). As loading controls, both blots were reprobed with
anti-actin antibody (Fig. 5, B and C, lower panels).
To delineate the role of Syk on pV-induced tyrosine phospho-
rylation of IB and subsequent interaction between tyrosine-
phosphorylated IB and the p85 subunit of PI 3-kinase,
MCF-7 cells were transfected with Syk-specific S-oligonucleo-
tides, and MDA-MB-231 cells were transfected with wild type
or SykK cDNA. Both cell lines were treated individually with
250 M pV and lysed in lysis buffer. The cell lysates containing
equal amounts of total proteins were immunoprecipitated with
anti-p85 antibody and detected by Western blot analysis us-
ing anti-phosphotyrosine antibody. MCF-7 cells transfected
with ASSyk showed a higher level of tyrosine phosphorylation
of IB (Fig. 5D, upper panel, lane 3), but this phosphorylation
was not detected in SSyk-transfected cells (lane 2) or the cells
transfected with LipofectAMINE Plus alone (lane 1). Similarly,
MDA-MB-231 cells transfected with wild type Syk cDNA
showed a reduction of tyrosine phosphorylation of IB (lane 6)
compared with SykK-transfected cells (lane 5) or cells trans-
fected with LipofectAMINE Plus alone (lane 4). As loading
controls, the same blots were reprobed with anti-actin antibody
(lower panel). These data suggest that Syk suppresses the
tyrosine phosphorylation of IB and subsequent interaction
between IB and PI 3-kinase in both cell lines.
To determine whether pV induces the colocalization of IB
with the p85 subunit of PI 3-kinase, both cell lines were
treated individually in absence or presence of 250 M pV, fixed,
and incubated with a mixture of anti-IB and anti-p85 an-
tibodies. These cells were incubated again with a mixture of
anti-rabbit FITC- and anti-mouse TRITC-conjugated IgG. The
immunofluorescence-labeled cells were detected by confocal mi-
croscopy. The data indicated that pV enhances the colocaliza-
tion of IB and PI 3-kinase in both cell lines (Fig. 5, E and F,
d–i) compared with untreated cells (a--c), but a higher level of
colocalization was observed in MDA-MB-231 cells (Fig. 5F).
Syk Inhibits Transcriptional Activity of NFB—Because Syk
suppressed the tyrosine phosphorylation of IB, we sought to
determine whether Syk has any role in the transactivation of
NFB in breast cancer cells. Accordingly, MCF-7 cells were
transfected with Syk-specific S-oligonucleotides and luciferase
reporter construct pNFB-Luc. Similarly, MDA-MB-231 cells
were transfected with wild type or SykK cDNA followed by
transfection with pNFB-Luc. The transfection efficiency was
normalized by cotransfecting the cells with pRL vector.
Changes in luciferase activity with respect to control were
calculated. The -fold changes were calculated, and the means of
triplicate determinations were plotted. In separate experi-
ments, these transfected cells were also treated individually
with increasing concentrations of piceatannol. The data indi-
cated that there was at least an 8-fold increase of NFB lucif-
erase activity in MCF-7 cells transfected with ASSyk compared
with LipofectAMINE Plus or SSyk-transfected cells (Fig. 6A).
In contrast, MDA-MB-231 cells transfected with wild type Syk
showed a 10-fold decrease in NFB luciferase activity com-
pared with cell transfected with SykK or LipofectAMINE Plus
alone (Fig. 6B). Piceatannol enhanced the NFB activity in
both of these cell lines in a dose-dependent manner (Fig. 6, A
and B). These data clearly demonstrated that Syk suppressed
the transcriptional activity of NFB in both cell lines.
To check the role of PI 3-kinase inhibitors (wortmannin or
LY294002) on pV-induced NFB activity, both cell lines were
transfected individually with pNFB-Luc and pRL in the pres-
ence of LipofectAMINE Plus. These transfected cells were then
treated with pV alone, pV with wortmannin, or pV with
LY294002. The data indicated that pV up-regulates the NFB
activity, but PI 3-kinase inhibitors (wortmannin and
LY294002) blocked the pV-induced NFB activity in both cell
lines (Fig. 6, C and D).
PI 3-Kinase and NFB Play Crucial Roles in uPA Secretion
and Cell Migration—To delineate whether PI 3-kinase plays
any role in uPA secretion, both MCF-7 and MDA-MB-231 cells
were treated individually with 250 M pV alone or pV with 100
nM wortmannin, or pV with 10 M LY294002. The cells were
lysed, and the lysates containing equal amounts of total pro-
teins were resolved by SDS-PAGE and analyzed by Western
blot analysis using anti-uPA antibody. The data indicated that
MCF-7 cells treated with pV showed a higher level of uPA
secretion (Fig. 7A, lane 2) compared with untreated cells (lane
1), whereas wortmannin (lane 3) and LY294002 (lane 4) sepa-
rately inhibited the pV-induced uPA secretion in these cells.
Similarly, pV also induced uPA secretion (lane 6) compared
with control (lane 5) in MDA-MB-231 cells, whereas both wort-
mannin (lane 7) and LY294002 (lane 8) blocked the pV-induced
uPA secretion in these cells.
We have also examined the effects of NFB modulators and
other agents on uPA secretion upon treating these cells (MCF-7
and MDA-MB-231) with SN-50, SN-50M, actinomycin-D, cur-
cumin, and PMA. These treated cell lysates containing equal
amounts of total proteins were separated by SDS-PAGE and
immunoblotted with anti-uPA antibody. The level of uPA ex-
pression was reduced significantly when MDA-MB-231 cells
were treated individually with SN-50 (NFB inhibitory pep-
tide) (Fig. 7C, lane 3), actinomycin-D (protein synthesis inhib-
itor) (lane 4), and curcumin (lane 5) compared with untreated
cells (lane 1). No changes of uPA secretion were observed in
cells treated with SN-50M (NFB control peptide) (lane 2). As
expected, PMA induces uPA secretion in these cells (lane 6).
Similar results were obtained in MCF-7 cells (Fig. 7B, lanes
1–6). The constitutive expression of uPA was much higher in
MDA-MB-231 cells compared with MCF-7 cells (Fig. 7, B and C,
lane 1). In all of these experiments, the uPA-specific bands
were quantified by densitometric analysis, and the values of
-fold changes are indicated.
Because the NFB-responsive element is present in the pro-
moter region of uPA, we sought to determine whether NFB-
regulated uPA expression has any role in the migration of
breast cancer cells. Accordingly, both cell lines were pretreated
individually with SN-50, SN-50M, actinomycin-D, curcumin,
and PMA and used for the migration assay. The results indi-
cated that SN-50, actinomycin-D, and curcumin separately in-
hibited the cell migration in both MCF-7 (Fig. 7D) and MDA-
MB-231 (Fig. 7E) cells compared with untreated cells. The cells
treated with SN-50M had no effect on suppression of cell mi-
gration. As expected, PMA induced cell migration in both cell
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lines (Fig. 7, D and E). These and previous data suggested that
uPA secretion and cell migration are regulated by PI 3-kinase
and NFB (30).
Syk Suppresses PI 3-Kinase-mediated uPA Secretion and
Cell Migration—To ascertain whether Syk regulates PI 3-
kinase-dependent uPA secretion, MCF-7 cells were either
transfected with Syk-specific S-oligonucleotides or treated with
piceatannol. These cells were used for the detection of uPA by
Western blot analysis using anti-uPA antibody. The cells trans-
fected with ASSyk showed a higher level of uPA expression
(Fig. 8A, lane 3) compared with Syk-transfected cells (lane 2) or
cells transfected with LipofectAMINE Plus alone (lane 1). The
level of uPA secretion was increased dose-dependently when
the cells were treated with increasing concentrations of piceat-
annol (Fig. 8B, lanes 2–4) and decreased when the cells were
incubated with increasing doses of wortmannin (Fig. 8C, lanes
2–4) or LY294002 (data not shown). The very low level of
constitutive uPA expression was observed in untreated cells
(Fig. 8, B and C, lane 1). The MDA-MB-231 cells transfected
with wild type Syk showed significant reduction of uPA secre-
tion (Fig. 8E, lane 2) compared with SykK-transfected cells
(lane 3) or cells transfected with LipofectAMINE Plus alone
(lane 1). Wortmannin inhibited the expression of uPA in these
cells in a dose-dependent manner (Fig. 8F, lanes 1–4). The
constitutive expression of uPA was much higher in highly
invasive MDA-MB-231 cells rather than low invasive MCF-7
cells (Fig. 8).
To delineate the effect of Syk on uPA-mediated cell migra-
tion, the MCF-7 cells were either treated with anti-uPA anti-
body or transfected with Syk-specific S-oligonucleotides and
then treated with anti-uPA antibody. The data showed that the
cell migration was reduced drastically when the cells were
treated with anti-uPA antibody (47%). The cells transfected
with ASSyk showed enhancement of cell migration (252%) com-
pared with SSyk-transfected cells or cells transfected with Li-
pofectAMINE Plus alone, whereas the ASSyk-transfected cells,
when treated with anti-uPA antibody, showed moderate cell
migration (153%) (Fig. 8D).
Similarly, MDA-MB-231 cells transfected with wild type Syk
cDNA followed by treatment with anti-uPA antibody reduced
the migration dramatically (22%) compared with wild type
Syk-transfected cells (24%) or cells treated with anti-uPA an-
tibody (47%) (Fig. 8G). The cells transfected with Lipo-
fectAMINE Plus alone or SykK showed maximum migration
(100%). These data demonstrated that Syk suppresses the PI
3-kinase-dependent uPA secretion and uPA-mediated cell mi-
gration in both MCF-7 and MDA-MB-231 cells.
FIG. 6. A and B, effect of Syk on NFB transactivation in MCF-7 (A) and MDA-MB-231 (B) cells. A, MCF-7 cells were transiently transfected with
Syk-specific S-oligonucleotides and luciferase reporter construct (pNFB-Luc) in the presence of LipofectAMINE Plus as described under
“Experimental Procedures.” The transfection efficiency was normalized by cotransfecting the cells with pRL vector. The non-S-oligonucleotide-
transfected cells were also treated with varying concentrations (0–10 M) of piceatannol. These cells were harvested, and luciferase activity was
measured. The cells transfected with ASSyk showed a dramatic increase of NFB luciferase activity compared with SSyk-transfected cells or cells
transfected with LipofectAMINE Plus alone. Piceatannol enhanced the luciferase activity in a dose-dependent manner. B, MDA-MB-231 cells were
transfected with Syk cDNA and pNFB-Luc using LipofectAMINE Plus as described under “Experimental Procedures.” The wild type Syk
cDNA-transfected cells were also treated with varying concentrations of piceatannol. MDA-MB-231 cells transfected with wild type Syk drastically
suppressed the luciferase activity compared with SykK-transfected cells or cells transfected with LipofectAMINE Plus alone. Piceatannol
enhanced the luciferase activity in wild type Syk-transfected cells. C and D, effects of pV and PI 3-kinase inhibitors on NFB transactivation in
MCF-7 (C) and MDA-MB-231 (D) cells. Both MCF-7 and MDA-MB-231 cells were transfected individually with pNFB-Luc. These cells were then
treated with pV alone, pV with 1–100 nM wortmannin or 1–10 M LY294002, and luciferase activity was measured. In both of these cell lines, pV
enhanced the luciferase activity, but pV-induced luciferase activity was blocked by wortmannin or LY294002 in a dose-dependent manner. The
values were normalized to Renilla luciferase activity. The -fold changes were calculated, and the results are expressed as the means S.E. of three
determination.
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DISCUSSION
In this study, we have demonstrated that Syk, a nonreceptor
protein-tyrosine kinase, inhibited PI 3-kinase activity and
subsequently suppressed cell motility in both highly invasive
(MDA-MB-231) and low invasive (MCF-7) breast cancer cells.
Syk is expressed in MCF-7 cells, but its expression is not
detectable in highly invasive MDA-MB-231 cells. The wild type
Syk cDNA was transfected in MDA-MB-231 cells, and its ex-
pression and autophosphorylation activity in these cells were
comparable with the endogenous Syk activity in MCF-7 cells
(data not shown). Furthermore, we have demonstrated that
Syk suppresses the pV-induced interaction of p85 subunit of PI
3-kinase and tyrosine-phosphorylated IB. Syk reduced the
NFB luciferase activity and piceatannol, a Syk inhibitor, en-
hanced the NFB activity in both MCF-7 and MDA-MB-231
cells. The inhibition of PI 3-kinase activity down-regulates the
NFB transactivation as well as cell motility in these cells.
Moreover, inhibition of PI 3-kinase and NFB activities by
their specific inhibitors reduced uPA secretion and cell motility
in these cells. Syk also inhibits the uPA secretion in both
MCF-7 and MDA-MB-231 cells. These data demonstrated that
Syk suppresses cell motility and down-regulates NFB activity
by inhibiting the PI 3-kinase activity and uPA secretion in
both MCF-7 and MDA-MB-231 cells.
ZAP-70, a nonreceptor protein-tyrosine kinase that shares
the same tandem SH2 domains with Syk at the amino termi-
nus, was not detected in the breast cancer cells (data not
shown). Previous reports have indicated that pV, a phosphoty-
rosine phosphatase inhibitor, induces autophosphorylation of
Syk in MCF-7 cells (13). However, our data revealed that pV
had no effect on activation of Syk in MCF-7 cells. Earlier
reports have shown that PI 3-kinase signaling is required for
FIG. 7. A, effects of pV and PI 3-kinase inhibitors on uPA secretion. MCF-7 and MDA-MB-231 cells were either treated with 250 M pV alone,
pV with 100 nM wortmannin or 10 M LY294002, and lysed. The level of uPA in the lysates was detected by Western blot analysis using anti-uPA
antibody. Lanes 1–4, MCF-7 cells. Lane 1, untreated cells; lane 2, with pV; lane 3, with wortmannin and pV; lane 4, with LY294002 and pV. Lanes
5–8, MDA-MB-231 cells. Lane 5, untreated cells; lane 6, with pV; lane 7, with wortmannin and pV; and lane 8, with LY294002 and pV. The arrow
indicates the uPA-specific band. B and C, effects of NFB modulators and other agents on uPA secretion. B, MCF-7 cells were treated individually
with 100 g/ml SN-50, 100 g/ml SN-50M, 10 g/ml actinomycin-D, 50 M curcumin, and 5 ng/ml PMA. The cells were lysed, and uPA expression
in the lysates was detected by Western blot analysis. Lane 1, untreated cells; lane 2, with SN-50M; lane 3, with SN-50; lane 4, with actinomycin-D;
lane 5, with curcumin; lane 6, with PMA. C, MDA-MB-231 cells were treated under the same conditions as those described above. Lane 1, untreated
cells; lane 2, with SN-50M; lane 3, with SN-50; lane 4, with actinomycin-D; lane 5, with curcumin; lane 6, with PMA. The level of uPA was decreased
significantly when both of these cell lines were pretreated with SN-50, actinomycin-D, or curcumin. As expected, PMA induced uPA expression.
Note that the constitutive expression of uPA was much higher in MDA-MB-231 cells compared with MCF-7 cells. The level of uPA was quantified
by densitometric analysis and is represented as -fold changes (A–C). D and E, effects of NFB modulators and other agents on cell migration. Both
MCF-7 (D) and MDA-MB-231 (E) cells were pretreated individually with SN-50M, SN-50, actinomycin-D, PMA, and curcumin under the same
conditions as described above. These treated cells were used for the migration assay as described under “Experimental Procedures.” The number
of untreated cells migrated was considered as 100%. The cells pretreated with SN-50, actinomycin-D, or curcumin showed a dramatic reduction
of cell migration compared with untreated cells or cells treated with SN-50M. As expected, PMA induced cell migration. The results are expressed
as the means  S.E. of three determinations.
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depolarization and cell migration of MCF-7 cells by insulin-like
growth factor I (31). The data also suggested that increased PI
3-kinase activity is correlated with the migratory potential
and metastatic activity of highly invasive breast cancer (MDA-
MB-231) cells (30). Using genetic (wild type Syk and SykK)
and pharmacological (piceatannol) inhibitors of Syk, we have
demonstrated that Syk is involved in the suppression of cell
motility, PI 3-kinase activity, and NFB-mediated uPA secre-
tion in both MCF-7 and MDA-MB-231 cells. The p110 isoforms
of PI 3-kinase played significant roles in cell migration, and
differential activation of specific p110 isoforms is responsible
for particular signaling events in different cell types (32, 33).
Recently, Sliva et al. (30) reported that the regulatory p85
subunit of PI 3-kinase is essential for enhanced migration of
metastatic tumor cells because overexpression of a dominant
negative regulatory subunit (p85DN) drastically reduced the
cell migration.
It has been documented recently that PI 3-kinase plays a
significant role in NFB activation in different cell types (34,
35). Tumor necrosis factor -induced NFB activation is not
affected by PI 3-kinase inhibitors (wortmannin and
LY294002). Similarly, a PI 3-kinase inhibitor has no effect on
interleukin-1-dependent IB degradation, nuclear transloca-
tion of NFB, and NFB-DNA binding (22). Our results dem-
onstrated that Syk down-regulates NFB transactivation by
inhibiting the interaction between the tyrosine-phosphorylated
IB and the p85 subunit of PI 3-kinase. Earlier reports have
shown that pV and tumor necrosis factor  induced NFB
FIG. 8. effects of Syk and PI 3-kinase inhibitor on uPA secretion and cell migration. A, MCF-7 cells were transfected with Syk-specific
S-oligonucleotides, lysed, and the level of uPA was detected by Western blot analysis. Lane 1, with LipofectAMINE Plus alone; lane 2, with SSyk;
lane 3, with ASSyk. B, MCF-7 cells were treated with 0–20 M piceatannol, and uPA was detected by Western blot analysis. Lane 1, untreated cells;
lane 2, with 1 M piceatannol; lane 3: with 10 M piceatannol; lane 4, with 20 M piceatannol. C, MCF-7 cells were treated with 0–100 nM
wortmannin, a PI 3-kinase inhibitor, and the level of uPA was analyzed. Lane 1, untreated cells; lane 2, with 10 nM wortmannin; lane 3, with 50
nM wortmannin; lane 4, with 100 nM wortmannin. Note that ASSyk and piceatannol enhanced the uPA secretion, whereas wortmannin reduced
the uPA secretion in these cells (A–C). D, MCF-7 cells were transfected with Syk-specific S-oligonucleotides as described above, treated with or
without 10 g/ml anti-uPA antibody, and used for migration assay. The cells transfected with ASSyk showed a dramatic increase in cell migration
compared with cells transfected with SSyk or LipofectAMINE Plus alone. Pretreatment of nontransfected cells with anti-uPA antibody showed a
drastic reduction of cell migration, whereas ASSyk-transfected cells, when treated with anti-uPA antibody, showed moderate inhibition of cell
migration. The number of cells migrated in LipofectAMINE Plus-transfected cells was considered as 100%. The results are expressed as the
means  S.E. of three determinations. E, MDA-MB-231 cells were transfected with Syk cDNA, and expression of uPA was detected by Western
blot analysis. Lane 1, with LipofectAMINE Plus; lane 2, with wild type Syk; lane 3, with SykK. F, MDA-MB-231 cells were treated with increasing
concentrations of wortmannin (0–100 nM), and the level of uPA was detected. Lane 1, untreated cells; lane 2, with 10 nM wortmannin; lane 3, with
50 nM wortmannin; lane 4, with 100 nM wortmannin. Wild type Syk and wortmannin suppressed the uPA secretion in these cells (E and F). Note
that the constitutive expression of uPA was higher in MDA-MB-231 cells compared with MCF-7 cells. G, MDA-MB-231 cells were transfected with
wild type or SykK cDNA, treated in the absence or presence of 10 g/ml anti-uPA antibody, and used for the cell migration assay. The wild type
Syk-transfected cells showed a dramatic reduction of cell migration compared with cells transfected with LipofectAMINE Plus alone or SykK. The
cells transfected with wild type Syk followed by treatment with anti-uPA antibody showed maximum inhibition of cell migration, whereas the
nontransfected cells treated with anti-uPA antibody showed moderate inhibition of cell migration. The number of cells migrated in LipofectAMINE
Plus-transfected cells was used as 100%. The results are expressed as the means  S.E. of three determinations. In all Western blot experiments,
the arrows indicate the uPA-specific band. The bands were quantified by densitometry and are represented in the form of a bar graph. The mean
values of triplicate experiments are indicated in the bar graph.
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activation in Jurkat cells, and only pV-induced activation of
NFB is inhibited by wortmannin (21). Both wortmannin and
LY294002 abrogated the transactivation of NFB but had no
effect on NFB-DNA binding in MDA-MB-231 cells (30). Our
data also revealed that Syk and PI 3-kinase inhibitors down-
regulate the transactivation of NFB but not NFB-DNA bind-
ing (data not shown) in both MCF-7 and MDA-MB-231 cells.
Thus we conclude that Syk-regulated transactivation of NFB
is independent of NFB-DNA binding in breast cancer cells.
We have shown that MDA-MB-231 cells transfected with
wild type Syk but not with SykK suppressed the cellular
migration and treatment of wild type Syk-transfected cells
with increasing concentrations of piceatannol enhanced the cell
migration in these cells. Both wortmannin and LY294002 in-
hibited, but pV induced the migration of MCF-7 and MDA-MB-
231 cells. The pV-induced migration is blocked by wortmannin
or LY294002 in these cells. Similarly, the NFB inhibitory
peptide SN-50, curcumin, and protein synthesis inhibitor (ac-
tinomycin-D) reduced cell migration. Pretreatment of non-
transfected or Syk-transfected cells with anti-uPA antibody
reduced the migration of these cells. These data suggested that
Syk suppressed the cell migration by down-regulating the con-
stitutively active NFB activation and uPA secretion by inhib-
iting the PI 3-kinase activity in breast cancer cells.
Our data also revealed that pV induces tyrosine phosphoryl-
ation of IB and subsequently enhances the interaction be-
tween tyrosine-phosphorylated IB with the p85 domain of
PI 3-kinase in a time-dependent manner in both cell lines. ST
638, a tyrosine kinase inhibitor, blocked the pV-induced tyro-
sine phosphorylation of IB. However, pV had no effect on
serine phosphorylation of IB in these cells, suggesting that
pV-induced transactivation of NFB occurs through tyrosine
phosphorylation of IB. Syk suppressed the tyrosine phospho-
rylation of IB and reduced the interaction between tyrosine-
phosphorylated IB and p85 subunit of PI 3-kinase. These
data demonstrated that Syk regulates the transactivation of
NFB by inhibiting the direct interaction of tyrosine-phospho-
rylated IB and the p85 domain of PI 3-kinase and suggested
an alternative pathway not involving the phosphorylation and
degradation of IB pathways.
Matrix metalloproteinases play a major role in the regula-
tion of cancer cell migration, extracellular matrix invasion, and
metastasis by degrading the extracellular matrix proteins (3, 4,
36). We and others have shown recently that NFB plays
significant roles in the activation of matrix metalloprotein-
ases-1, -2, -3, and -9 (27, 37, 38). uPA is also responsible for the
migration and regulation of matrix metalloproteinases activa-
tion through NFB-mediated pathways (39). In this study, we
have detected the level of uPA in both highly invasive (MDA-
MB-231) and low invasive (MCF-7) breast cancer cells. The
constitutive secretion of uPA is significantly higher in MDA-
MB-231 cells; however, a low level of uPA expression is ob-
served in MCF-7 cells. The data also indicate that Syk down-
regulates whereas pV up-regulates the uPA production in these
cells. The PI 3-kinase inhibitors wortmannin and LY294002 or
the NFB inhibitor SN-50 reduced uPA secretion, especially in
MDA-MB-231 cells.
In summary, we have demonstrated for the first time that
overexpression of wild type Syk kinase but not the SykK
suppresses cell motility and reduces the activation of PI 3-
kinase in MDA-MB-231 cells. In contrast, in ASSyk but not
SSyk, when transfected to the MCF-7 cells, the level of PI
3-kinase activity as well as cell motility were increased. In the
wild type Syk cDNA-transfected MDA-MB-231 cells, when
treated with piceatannol, a Syk inhibitor, PI 3-kinase activity
increased. pV, a tyrosine phosphatase inhibitor, enhances the
activity of PI 3-kinase and induces the interaction between
p85, the regulatory subunit of PI 3-kinase, and IB through
tyrosine phosphorylation of IB. Syk suppresses the transac-
tivation of NFB by inhibiting the tyrosine phosphorylation of
IB. PI 3-kinase inhibitor reduces the pV-induced transacti-
vation of NFB. Both PI 3-kinase inhibitors wortmannin and
LY294002 and NFB inhibitory peptide SN-50 suppress cell
motility, indicating that PI 3-kinase and NFB play signifi-
cant roles in this process. ASSyk-transfected MCF-7 cells en-
hanced uPA secretion, whereas wild type Syk
cDNA-transfected MDA-MB-231 cells reduced uPA production,
indicating that Syk down-regulates uPA secretion. These data
suggested that Syk suppresses the NFB transactivation by
inhibiting the direct interaction of tyrosine-phosphorylated
IB with the p85 domain of PI 3-kinase in breast cancer
cells. Finally, these data demonstrated that Syk down-regu-
lates PI 3-kinase activity and suppresses the constitutive
NFB activity and uPA secretion that ultimately lead to the
suppression of cell motility of breast cancer cells (Fig. 9). These
findings may be useful in designing novel therapeutic interven-
tions using Syk as a target molecule that will disrupt the PI
3-kinase and NFB signaling pathways, resulting in reduction
of uPA secretion and consequent blocking of invasiveness, mi-
gration, and metastatic spread of breast cancer.
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